Confo Therapeutics Announces Encouraging Preclinical Data for Post-bariatric Hypoglycemia Candidate CFTX-2034 at ENDO 2026
Data support the potential of CFTX-2034 as a first-in-class treatment for PBH and advancement toward Phase 1 clinical development Ghent, Belgium – June 15, 2026 – Confo Therapeutics, a clinical-stage